论坛 › SEO优化 › 2019AACR会议重点：十大难治肿瘤的重磅突破汇总

9q13nh 发表于 2024-5-29 08:46:05

2019AACR会议重点：十大难治肿瘤的重磅突破汇总

<img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aaBiaKGaMrjXKHVnLMib2hqxQONUpLPPG90puKT0haF8ypxGoHHb6lS7g/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">今年3月29日-4月3日在美国ATLANTA举办的AACR（美国癌症<span style="color: black;">科研</span>协会）年会正在召开。这几天，会议上<span style="color: black;">已然</span>报出了<span style="color: black;">各样</span>肿瘤治疗新突破，<span style="color: black;">持续</span>惊艳全场。免疫新药、新靶点靶药、新的联合<span style="color: black;">方法</span><span style="color: black;">不可胜数</span>，各大癌种新数据涌现不止。今天，<span style="color: black;">博主</span>在会议落幕之前，先给<span style="color: black;">大众</span>汇总会上新数据<span style="color: black;">报告</span>，带<span style="color: black;">大众</span>跟上肿瘤新<span style="color: black;">发展</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">非小细胞肺癌</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">免疫靶向齐发力</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1.沃利替尼+奥希替尼克服EGFR-TKI耐药</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">MET扩增为EGFR突变NSCLC<span style="color: black;">病人</span>靶向治疗耐药的一大<span style="color: black;">原由</span>。一/二代TKI耐药后，大<span style="color: black;">大概</span>5%-10%的<span style="color: black;">病人</span><span style="color: black;">显现</span>MET扩增，而三代TKI耐药后<span style="color: black;">显现</span>MET扩增的比例为25%。可见<span style="color: black;">解决</span>MET扩增是耐药后的一大处理<span style="color: black;">办法</span>。会议上<span style="color: black;">报告</span>了国产MET-TKI沃利替尼+三代EGFR药奥希替尼的TATTON<span style="color: black;">科研</span>结果，成绩亮眼。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">该1b期<span style="color: black;">实验</span>分为两个队列：队列一纳入1/2代EGFR-TKI治疗<span style="color: black;">发展</span>后T790M阴性MET扩增阳性的晚期NSCLC<span style="color: black;">病人</span>；队列二纳入三代EGFR-TKI<span style="color: black;">发展</span>后MET扩增阳性NSCLC<span style="color: black;">病人</span>，两个队列都<span style="color: black;">运用</span>奥希替尼80mg/天+沃利替尼600mg/天治疗。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">队列一共分析了46例<span style="color: black;">病人</span>，80%为亚裔，67%<span style="color: black;">病人</span>既往治疗线数为1。<span style="color: black;">ORR（客观有效率）为52%，DCR（<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率）达到87%。</span>DOR（反应<span style="color: black;">连续</span>时间）为7.1个月。安全性方面，16例<span style="color: black;">病人</span><span style="color: black;">由于</span>AE（不良反应）而停药，<span style="color: black;">显现</span>2例AE<span style="color: black;">关联</span>性死亡（1例与沃利替尼治疗副<span style="color: black;">功效</span><span style="color: black;">相关</span>，另一例与治疗<span style="color: black;">没</span>关）。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aiaQ8u90MYrXuf9B9KlFgwtqSqoRLNepY2I5Ua8RPAJsLwCZokAN0HUQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">队列二共分析48例<span style="color: black;">病人</span>，77%为亚裔。44%<span style="color: black;">病人</span>既往经过二线治疗，27%接受过3线，27%接受过≥3线。<span style="color: black;">ORR为25%，DCR为69%，DOR为9.7个月</span>。安全性方面，各有5例<span style="color: black;">病人</span>因AE而停用沃利替尼或奥希替尼。2例<span style="color: black;">病人</span>死亡，但判断与治疗<span style="color: black;">没</span>关。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aO9yxvvcHsziaVxPJVvibuGJaqjOXfribXFsHn8WZNRpqyjSsIwjkR6sWQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">初步结果<span style="color: black;">表示</span>，奥希替尼联合沃利替尼能有效的克制EGFR-TKI耐药后<span style="color: black;">显现</span>的MET扩增。<span style="color: black;">没</span>论是一/二代TKI耐药，或是三代耐药，DCR都能稳定在69%以上，安全性尚可接受</span>。<span style="color: black;">日前</span>已有II期SAVANNAH<span style="color: black;">科研</span>正开展，期待后续结果。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2.Keynote189亚组分析：脑转及肝转<span style="color: black;">病人</span><span style="color: black;">亦</span>能从免疫获益</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">会议<span style="color: black;">报告</span>了Keynote189的肝转移及脑转移的亚组分析，该<span style="color: black;">实验</span>纳入616例初治的晚期非鳞状NSCLC<span style="color: black;">病人</span>，用Keytruda+培美曲塞+铂类或培美曲赛+铂类治疗。基线肝脏转移（16%，n=66）或脑转移（18%，n=73）<span style="color: black;">病人</span>中分析的出，<span style="color: black;">与单用化疗相比，Keytruda联合化疗可使脑转移<span style="color: black;">病人</span>的死亡率降低59%（HR=0.41），脑转移<span style="color: black;">病人</span>中位OS分别为联合组19.2m vs 化疗组7.5m，PD1+化疗延长了将近两倍！</span>PFS（<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期）方面，K药+化疗成功将脑转移<span style="color: black;">病人</span>的<span style="color: black;">疾患</span><span style="color: black;">发展</span>或死亡<span style="color: black;">危害</span>降低了58%（HR=0.42），中位PFS分别为6.9m vs 4.7m。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aiarfSKDX8hSYUJVETRaZBiaDK6J5obvW2chE4Mcib9Ar37HibLywESpOOA/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">K药+化疗可使肝脏转移<span style="color: black;">病人</span>的死亡率降低38%（HR=0.62），两组的中位OS分别为12.6m vs 6.6m，PD1+化疗的OS延长一倍。</span><span style="color: black;">另外</span>，Keytruda联合化疗<span style="color: black;">亦</span>改善了PFS，肝脏转移<span style="color: black;">病人</span>的<span style="color: black;">疾患</span><span style="color: black;">发展</span>或死亡<span style="color: black;">危害</span>降低了48%（HR=0.52）。中位PFS分别为6.1m vs 3.4m。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aKkWMQkfmQ9ajUt23eKuCibo9KAqEfqMeLLhWibQ6RZnd4REE0ypYblTQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">报告</span>中，PD1+化疗展现了不错的肝转移及脑转移疗效。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3.沃利替尼治疗MET14外显子跳跃缺失突变的II期结果满意</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">AACR上，陆舜教授主持了沃利替尼（savolitinib）单药的II期<span style="color: black;">科研</span><span style="color: black;">报告</span>。该<span style="color: black;">实验</span>纳入了31例MET14跳跃缺失突变的肺肉瘤样癌（PSC）及其他种类的晚期NSCLC<span style="color: black;">病人</span>，41.5%的<span style="color: black;">病人</span>为初治，19.5%的<span style="color: black;">病人</span>基线有脑转移。按RECIST1.1结果<span style="color: black;">评定</span>，<span style="color: black;">ORR为54.8%，DCR达到了93.5%之高，<span style="color: black;">掌控</span>率极强。</span>中位PFS还未成熟。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6ahZRRU8nmVzExsgpJsUUlqCZuvmibptRbdl5MEGDhOFsx37llhOqlKbg/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">安全性方面，大部分为1/2级AE，治疗<span style="color: black;">关联</span>性严重AE占了17.1%，22%的<span style="color: black;">病人</span>因AE而停药，6例<span style="color: black;">病人</span>死亡（1例为<span style="color: black;">疾患</span><span style="color: black;">发展</span>，1例可能为AE，1例未知，3例与治疗<span style="color: black;">没</span>关）。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span><span style="color: black;">显示</span>，沃利替尼对MET14跳跃突变的晚期NSCLC<span style="color: black;">病人</span>疗效亮眼，在脑转移中<span style="color: black;">亦</span>展现了抗癌活性，<span style="color: black;">日前</span><span style="color: black;">实验</span>继续招募，<span style="color: black;"><strong style="color: blue;">我司<span style="color: black;">亦</span>有对接沃利替尼<span style="color: black;">实验</span>项目，有意<span style="color: black;">能够</span>文末扫码进群报名。一旦入组，可<span style="color: black;">以避免</span><span style="color: black;">花费</span>好药！</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">小细胞肺癌</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">PD1守住后线，部分<span style="color: black;">病人</span><span style="color: black;">长时间</span>未复发</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">会议<span style="color: black;">报告</span>了keynote028及keynote158的结果，两项<span style="color: black;">科研</span>均为开放标签、非随机、多队列、“篮子”<span style="color: black;">科研</span>，<span style="color: black;">评定</span>了Keytruda单药用于既往接受过≥2线治疗的广泛期SCLC<span style="color: black;">病人</span>的疗法。Keynote028中<span style="color: black;">病人</span>接受K药10mg/<span style="color: black;">公斤</span>，q2w；keynote158中<span style="color: black;">病人</span>接受K药200mg，q3w。中位随访时间为7.7个月（范围0.5-48.7）。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">两项<span style="color: black;">科研</span>中共83例符合疗效分析（keynote158，n=64；keynote028，n=19）。<span style="color: black;">分析<span style="color: black;">表示</span>，Keytruda单药治疗的ORR为19.3%（n=16），其中2例CR完全缓解，14例PR部分缓解。缓解<span style="color: black;">病人</span><span style="color: black;">其中</span>PDL1阳性（≥1%）占14例。有超过一半的（n=9/16）<span style="color: black;">病人</span>缓解<span style="color: black;">连续</span>时间在18个月或更长，中位DOR尚未达到。</span>中位OS为7.7个月，12个月和24个月的OS率分别为34.3%和20.7%。中位PFS为2.0个月，12个月和24个月的PFS率分别为16.9%和13.1%。≥3级AE<span style="color: black;">出现</span>率为10%。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Keytruda单药治疗在既往已接受≥2种<span style="color: black;">方法</span>的晚期SCLC<span style="color: black;">病人</span>中表现出了良好的疗效，并且缓解持久，PD1长效<span style="color: black;">优良</span>展现<span style="color: black;">没</span>遗。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">三阴乳腺癌<span style="color: black;">发展</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">新<span style="color: black;">方法</span>登上台</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1.溶瘤病毒联合化疗辅助治疗创佳绩</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">三阴乳腺癌在术后<span style="color: black;">通常</span>多用紫杉烷/蒽环素类化疗，病理上完全缓解（pCR）大约为30%。而pCR越高，预后越好。为了<span style="color: black;">加强</span>术后辅助治疗疗效，一项1期溶瘤病毒T-VEC（viral oncolytic talimogene laherparepvec）+化疗（先用紫杉醇，后阿霉素+环磷酰胺）术后辅助的<span style="color: black;">实验</span>展开，共分析了9例<span style="color: black;">病人</span>，6例<span style="color: black;">疾患</span>分期为2期，3例为3期。结果<span style="color: black;">表示</span>，共有5例（56%）达到了pCR，其余4例只剩下小残留病灶。<span style="color: black;">实验</span>的安全性良好。后续将展开2期<span style="color: black;">实验</span>，进一步验证疗效。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2.免疫+靶向+化疗一线ORR飚至73%</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">会议上<span style="color: black;">颁布</span>了PD-L1单抗Tecentriq（atezolizumab，<span style="color: black;">叫作</span>T药），与ipatasertib和化疗（紫杉醇或白蛋白紫杉醇）相结合，<span style="color: black;">做为</span>一线疗法治疗三阴性乳腺癌的1b期临床<span style="color: black;">实验</span>结果。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Ipatasertib是一款靶向P13K/AKT信号通路的口服特异性<span style="color: black;">控制</span>剂，能够与AKT的三种亚型相结合PI3K/AKT信号通路被认为可能是肿瘤细胞对免疫<span style="color: black;">检测</span>点抑制剂产生抗性的机制之一，<span style="color: black;">因此呢</span><span style="color: black;">控制</span>PI3K/AKT信号通路可能逆转肿瘤细胞对免疫疗法的抗性。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">实验</span>结果<span style="color: black;">显示</span>，这一组合疗法<span style="color: black;">做为</span>一线治疗，在不<span style="color: black;">思虑</span><span style="color: black;">病人</span>PD-L1表达水平和PIK3CA/AKT1/PTEN基因突变的<span style="color: black;">状况</span>下，<span style="color: black;">ORR达到73%，三<span style="color: black;">方法</span>联合有望创下三阴乳腺癌一线疗效新高。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">结直肠癌</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">durva+treme+放疗<span style="color: black;">解决</span>后线MSS型<span style="color: black;">病人</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">针对</span>MSS型结直肠癌<span style="color: black;">病人</span>，<span style="color: black;">运用</span>免疫治疗的效果<span style="color: black;">不良</span>，而临床前<span style="color: black;">实验</span><span style="color: black;">发掘</span>免疫+放疗对这类<span style="color: black;">病人</span>有<span style="color: black;">必定</span><span style="color: black;">功效</span>。这项II期<span style="color: black;">实验</span>纳入了化疗失败后的MSS型晚期结直肠癌<span style="color: black;">病人</span>，接受3次SBRT（立体定向放疗）治疗后，<span style="color: black;">运用</span>durvalumab（Imfinzi）+tremelimumab（CTLA4单抗）。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aWk6clYnqXPwGHVaqx3dia9XuMRBwawNDUbNnhvR71GoAlGbC3hiaicZpQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">共分析了20例<span style="color: black;">病人</span>，有2例<span style="color: black;">病人</span><span style="color: black;">显现</span>PR，疗效都<span style="color: black;">连续</span>了44周及44周以上，<span style="color: black;">另一</span>2例<span style="color: black;">病人</span><span style="color: black;">显现</span><span style="color: black;">疾患</span>稳定，DCR为20%。16例<span style="color: black;">病人</span><span style="color: black;">显现</span>≥3级AE，1例<span style="color: black;">病人</span><span style="color: black;">显现</span>死亡。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">针对</span>后线难治性MSS型结直肠癌<span style="color: black;">病人</span>，治疗<span style="color: black;">方法</span>非常有限，该免疫联合<span style="color: black;">方法</span>展现了<span style="color: black;">必定</span>的疗效。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">黑色素瘤</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">K药+靶向药克服PD1耐药</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">会上<span style="color: black;">颁布</span>了HDAC<span style="color: black;">控制</span>剂entinostat与K药联用，治疗PD1耐药的晚期黑色素瘤<span style="color: black;">病人</span>的2期临床结果。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Entinostat是一款HDAC<span style="color: black;">控制</span>剂，HDAC是<span style="color: black;">掌控</span>组蛋白乙酰化状态的<span style="color: black;">要紧</span>蛋白酶。<span style="color: black;">科研</span><span style="color: black;">显示</span>，阻断HDAC活性可能<span style="color: black;">控制</span>骨髓<span style="color: black;">源自</span>的<span style="color: black;">控制</span>细胞（MDSC）和调节性T细胞（Treg）的生成。这两种细胞都能够<span style="color: black;">控制</span>效应T细胞的免疫反应。<span style="color: black;">因此呢</span>，entinostat与免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂联用，可能<span style="color: black;">加强</span>免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂的效果。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6av9nZMkyu7fP9J9KkXk2MxwnGic5bsm7OSr9MquZ3HY7ELUdFnGtmg0w/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">照片</span><span style="color: black;">源自</span>：Syndax<span style="color: black;">机构</span>官网</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在ENCORE 601<span style="color: black;">实验</span>中，entinostat与Keytruda联用在<span style="color: black;">病人</span>ORR达到19%，中位DOR为13个月。<span style="color: black;">值得<span style="color: black;">重视</span>的是，这些<span style="color: black;">病人</span><span style="color: black;">不仅</span>接受过PD-1治疗，<span style="color: black;">况且</span>其中70%的<span style="color: black;">病人</span>接受过伊匹单抗（CTLA4<span style="color: black;">控制</span>剂）的治疗，并且<span style="color: black;">疾患</span>继续恶化。在这些<span style="color: black;">已然</span>对两种免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂产生抗性的<span style="color: black;">病人</span>中产生疗效殊为<span style="color: black;">很难</span>，</span>后期前景值得期待。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">胰腺癌</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">O药+CD40<span style="color: black;">控制</span>剂新<span style="color: black;">方法</span><span style="color: black;">显现</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">会上新<span style="color: black;">方法</span><span style="color: black;">持续</span>，O药（Opdivo）联合癌症免疫疗法APX005M治疗<span style="color: black;">包含</span>转移性胰腺癌和黑色素瘤等多种实体瘤的<span style="color: black;">实验</span>结果得到<span style="color: black;">颁布</span>。APX005M是Apexigen<span style="color: black;">研发</span>的抗CD40激动性抗体。CD40是一种共刺激受体，它对激活先天和适应性免疫系统都起到<span style="color: black;">重要</span>性的<span style="color: black;">功效</span>。APX005M<span style="color: black;">能够</span><span style="color: black;">做为</span>单药疗法<span style="color: black;">或</span>与其它免疫疗法联用，激发免疫系统的多个部分联合攻击癌症。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aR0VRFFD0Gzev30nyDrxia6fCUKp3rn2zEH3AyicSuzHdaxKJRSWTlNPQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">照片</span><span style="color: black;">源自</span>：Apexigen<span style="color: black;">机构</span>官网</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在晚期胰腺癌的1b期临床<span style="color: black;">实验</span>中，APX005M与化疗联用，治疗<span style="color: black;">已然</span>接受过PD-1/PD-L1单抗治疗的<span style="color: black;">病人</span>，其中50%的<span style="color: black;">病人</span><span style="color: black;">同期</span><span style="color: black;">运用</span>nivolumab。<span style="color: black;">中期<span style="color: black;">实验</span>结果<span style="color: black;">显示</span>，在24名<span style="color: black;">病人</span>中20名<span style="color: black;">病人</span>的肿瘤<span style="color: black;">显现</span>缩小。部分<span style="color: black;">病人</span>接受治疗超过1年时间，表现出持久缓解</span>。<span style="color: black;">况且</span>APX005M表现出良好的安全性和耐受性。<span style="color: black;">实验</span>中<span style="color: black;">方法</span>新颖，疗效<span style="color: black;">亦</span>亮眼，值得期待。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">前列腺癌</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">K药+新免疫疗法取得新突破</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">难治的去势抵抗性前列腺癌<span style="color: black;">显现</span>新<span style="color: black;">方法</span>。会上<span style="color: black;">报告</span>了K药+ ADXS-PSA治疗晚期去势抵抗性前列腺癌<span style="color: black;">病人</span>的1/2期临床<span style="color: black;">实验</span>结果。ADXS-PSA是一款基于李斯特菌（Listeria monocytogenes）的免疫疗法，它<span style="color: black;">运用</span>经过生物工程改造过的减毒李斯特菌<span style="color: black;">做为</span>载体，将PSA抗原直接递送给抗原呈递细胞，从而激发免疫系统的免疫反应。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6a4fLR7RLcDtf991PZgxhiaZyw62UwmN3X2Rf9lYAs8D0MxDc0ibBCABgQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">照片</span><span style="color: black;">源自</span>：Advaxis<span style="color: black;">机构</span>官网</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在名为KEYNOTE-046的临床<span style="color: black;">实验</span>中，<span style="color: black;">已然</span>接受<span style="color: black;">太多</span>次前期治疗的前列腺癌<span style="color: black;">病人</span>接受了ADXS-PSA联合Keytruda治疗。<span style="color: black;">实验</span>结果<span style="color: black;">显示</span>，<span style="color: black;">37名<span style="color: black;">病人</span>的中位OS达到21.1个月</span>。<span style="color: black;">同期</span>，接受组合疗法的<span style="color: black;">病人</span>中，75%的<span style="color: black;">病人</span>表现出针对PSA的T细胞反应。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">CAR-T在实体瘤取得成绩</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">间皮瘤及肉瘤<span style="color: black;">显现</span>新<span style="color: black;">期盼</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">始终</span><span style="color: black;">败兴</span>，CAR-T疗法在治疗血液癌症方面的效果较好，但在实体瘤的<span style="color: black;">实验</span>却遭到多处碰壁，<span style="color: black;">发展</span>缓慢，可能与实体瘤的异质性更<span style="color: black;">繁杂</span><span style="color: black;">相关</span>，<span style="color: black;">增多</span>了CAR-T细胞<span style="color: black;">精细</span>靶向肿瘤的难度。这次大会上<span style="color: black;">报告</span>了两项实体瘤的突破，惊艳在座。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在由MSK 癌症中心的胸外科副<span style="color: black;">专家</span>Prasad Adusumilli领导的<span style="color: black;">科研</span>中，共21名<span style="color: black;">身患</span>恶性胸膜<span style="color: black;">疾患</span>的<span style="color: black;">病人</span>（其中有19位<span style="color: black;">身患</span>间皮瘤，一位是转移性肺癌、另一位是转移性乳腺癌）接受了CAR-T治疗。结果<span style="color: black;">表示</span>，这可能是一种更有效的治疗策略。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1.间皮瘤</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">间皮瘤的预后效果<span style="color: black;">尤其</span>差，2003年<span style="color: black;">获准</span>的铂类化疗中位OS<span style="color: black;">仅有</span>3个月，之后的K药等在内的免疫治疗的<span style="color: black;">初期</span><span style="color: black;">实验</span>仅仅表现出轻微的反应率。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">会上<span style="color: black;">报告</span>了CAR-T（IcasM28z），该疗法靶向一种<span style="color: black;">都数</span>癌细胞表面都会表达的蛋白——间皮素（mesothelin）。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">实验</span>共纳入21例晚期实体瘤<span style="color: black;">病人</span>（19例间皮瘤，1例肺癌，1例乳腺癌），在接受CAR-T和<span style="color: black;">最少</span>三个周期的抗PD-1治疗的11名<span style="color: black;">病人</span>中，有8名<span style="color: black;">病人</span>的肿瘤缩小。其中有两名<span style="color: black;">病人</span>在60周和32周时<span style="color: black;">始终</span>对治疗有完全的缓解反应。<span style="color: black;">要紧</span>的是，临床<span style="color: black;">实验</span>并<span style="color: black;">无</span><span style="color: black;">显现</span>CAR-T细胞<span style="color: black;">关联</span>毒性高于2级的现象，<span style="color: black;">况且</span><span style="color: black;">无</span><span style="color: black;">病人</span><span style="color: black;">出现</span>神经毒性<span style="color: black;">或</span>细胞因子释放<span style="color: black;">综合症</span>（<span style="color: black;">平常</span>副<span style="color: black;">功效</span>）。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2.肉瘤</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">会上<span style="color: black;">报告</span>了另一靶向HER2的CAR-T疗法。结果<span style="color: black;">一样</span>让人欣慰。<span style="color: black;">科研</span><span style="color: black;">已然</span>证实，相比于曲妥珠单抗，靶向HER2的CAR-T细胞能够更好的靶向表达低水平HER2的肿瘤细胞。在Ⅰ期<span style="color: black;">实验</span>中，共纳入了10例晚期HER2阳性肉瘤<span style="color: black;">病人</span>（其中5例骨肉瘤，3例横纹肌肉瘤，1例尤文肉瘤和1例滑膜肉瘤），<span style="color: black;">她们</span>接受了多达3次的CAR-T细胞注射。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">结果<span style="color: black;">表示</span>，一位横纹肌肉瘤<span style="color: black;">病人</span>（<span style="color: black;">已然</span>转移至骨髓中）在接受CAR-T治疗后<span style="color: black;">显现</span>了12个月的缓解期，<span style="color: black;">然则</span>后来依然复发了。<span style="color: black;">一样</span>，这项<span style="color: black;">科研</span><span style="color: black;">亦</span><span style="color: black;">无</span><span style="color: black;">显现</span>神经毒性，<span style="color: black;">然则</span>有2名<span style="color: black;">病人</span><span style="color: black;">显现</span>了细胞因子释放<span style="color: black;">综合症</span>（<span style="color: black;">危害</span>大于2级）。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">淋巴瘤</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">RTK靶向药及PI3K靶向药各显神通</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在另一项引人注目的<span style="color: black;">报告</span>是，RTK<span style="color: black;">控制</span>剂Xospata（gilteritinib）报出满意的OS。这款<span style="color: black;">药品</span>能有效<span style="color: black;">控制</span>FLT3，这是AML<span style="color: black;">病人</span>中<span style="color: black;">平常</span>的遗传变异，约占所有病例的25%-30%。去年11月，这款新药得到了美国FDA的首次<span style="color: black;">准许</span>，治疗带有FLT3基因突变的晚期AML（急性骨髓性淋巴瘤）<span style="color: black;">病人</span>。而会上<span style="color: black;">颁布</span>的数据<span style="color: black;">显示</span>，接受Xospata治疗的<span style="color: black;">病人</span>，<span style="color: black;">中位OS为9.3个月</span>，而接受<span style="color: black;">解救</span>性化疗（salvage chemotherapy）的对照组，其中位OS为5.6个月（HR=0.637；95% CI：0.490，0.830；p=0.007）。<span style="color: black;">另外</span>，治疗组<span style="color: black;">最少</span>存活一年的概率是37%，为对照组（17%）的两倍有余。<span style="color: black;">针对</span><span style="color: black;">哪些</span>预后较差的FLT3阳性AML<span style="color: black;">病人</span>，这款新药带来了全新的<span style="color: black;">期盼</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PI3K-δ<span style="color: black;">控制</span>剂umbralisib<span style="color: black;">亦</span>在一项2期临床<span style="color: black;">实验</span>中取得了可喜的成绩。在难治性/复发性边缘区淋巴瘤（marginal zone lymphoma）的治疗中，<span style="color: black;">实验</span>纳入了38例<span style="color: black;">病人</span>，<span style="color: black;">ORR为55%，4名为CR。这款疗法的DCR高达84%，达到一年<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>的<span style="color: black;">病人</span>比例<span style="color: black;">亦</span>有71%</span>。这款在今年1月斩获美国FDA突破性疗法认定的创新药，有望在将来给<span style="color: black;">咱们</span>带来<span style="color: black;">更加多</span>惊喜。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">参考文献：</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Proceedings of the American Association for Cancer Research AACR ANNUAL MEETING 2019 • Volume 60</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">版权声明</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">本文部分<span style="color: black;">照片</span>源于<span style="color: black;">期盼</span>树，专注八卦的小和尚</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">版权归找药宝典所有，任何个人或<span style="color: black;">公司</span>转载需<span style="color: black;">得到</span>找药宝典授权，在授权范围内<span style="color: black;">运用</span>，并标注<span style="color: black;">源自</span>“找药宝典”。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">找药宝典<span style="color: black;">病人</span>讨论群</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">找药宝典已开通<strong style="color: blue;"><span style="color: black;">多个癌种<span style="color: black;">病人</span>讨论群</span></strong>，在<span style="color: black;">这儿</span>您<span style="color: black;">能够</span>与其他<span style="color: black;">病人</span>交流病情，讨论治疗<span style="color: black;">方法</span>，分享抗癌经验，寻求<span style="color: black;">帮忙</span>。<strong style="color: blue;">扫下方二维码添加管理员，备注癌种，<span style="color: black;">经过</span>验证后邀请入群。<span style="color: black;">（PS：管理员繁忙，备注癌种会<span style="color: black;">提高</span>入群机会）</span></strong></p><img src="https://mmbiz.qpic.cn/mmbiz_jpg/oZVJebibh9RlibFqUzrViaRUSZvO7POth0x6nWib8Oz6U547XWwwx9VBBM7aT7pftprOgB5gmHRFXOuUibxeG7Q7Tbg/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">管理员二维码</p><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6aTaHmhrp8QvIao1HjbCiaU42HDIozMyd2YicNxV6Xn7HUic6TeMC3YODqQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6awvtpFxYhjmYowVIebN57vwuFvZIAbWwmxAlib29j7fe6rFCS9CSv9fQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">- 找药宝典 -</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">六大服务助力肿瘤治疗</span></p><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/oZVJebibh9Rnyb8hS3mXOSOWckj3eam6arVaKr2liafc7HiakhQHuI0NFA9qQibPFM7rib3zd0lR8urIDvAlarkekrQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></a><a style="color: black;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></a><a style="color: black;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></a><a style="color: black;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></a><a style="color: black;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></a><a style="color: black;"><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">癌症<span style="color: black;">病人</span>如治疗遇到困境，可点击文末<span style="color: black;"><strong style="color: blue;">“阅读原文”</strong></span>提交病情，<span style="color: black;">咱们</span>会为您<span style="color: black;">供给</span>综合国内外治疗<span style="color: black;">方法</span>的个性化治疗<span style="color: black;">意见</span>，如有合适<span style="color: black;">实验</span>参加<span style="color: black;">亦</span>会积极<span style="color: black;">举荐</span>。</p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">翳安健康专注于肿瘤<span style="color: black;">行业</span>，<span style="color: black;">经过</span><span style="color: black;">微X</span>公众号“找药宝典”、“招募宝典”等多个平台，为该<span style="color: black;">行业</span>的<span style="color: black;">病人</span>在<span style="color: black;">全世界</span>范围内寻求最有效的治疗手段。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">咱们</span><span style="color: black;">经过</span><span style="color: black;">供给</span>癌症临床<span style="color: black;">实验</span>招募，海外<span style="color: black;">看病</span>服务、基因检测援助、搭建<span style="color: black;">病人</span>讨论平台等多项服务，为更好<span style="color: black;">处理</span><span style="color: black;">病人</span>在抗癌路上面临的困境而<span style="color: black;">奋斗</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">癌症可怕，但<span style="color: black;">咱们</span>与您携手抗癌！</p>

b1gc8v 发表于 2024-10-5 00:14:21

回顾过去一年，是艰难的一年；展望未来，是辉煌的一年。

4lqedz 发表于 2024-10-5 16:11:57

期待楼主的下一次分享！”

qzmjef 发表于 2024-10-14 03:36:59

期待楼主的下一次分享！”

wrjc1hod 发表于 2024-10-24 04:13:38

“NB”（牛×的缩写，表示叹为观止）‌

查看完整版本: 2019AACR会议重点：十大难治肿瘤的重磅突破汇总